TRVITrevi Therapeutics, Inc.

Healthcare
$13.20+62% 1Y

The financials

Trevi Therapeutics, Inc. by the numbers

The next results filing is expected around Nov 12, 2026, the same week as a year ago.

Trevi Therapeutics, Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$21M−$14Mn/a
Net income−$18M−$12Mn/a
Diluted EPS−$0.11−$0.09n/a

Biotechnology

Ranks #183 of 196 by RyuScore

Compare peers
CLDX+2.1%
Celldex Therapeutics, Inc.
KLRA+16%
Kailera Therapeutics, Inc.
IRON+2.2%
Disc Medicine, Inc.
MBX+0.16%
MBX Biosciences, Inc.
TARS+1.2%
Tarsus Pharmaceuticals, Inc.
SLBT-1.3%
SL Science Holding Limited